Cenote gives D2C and telehealth leads a persistent sales conversation

Cenote is built for D2C and telehealth operators whose marketing has already paid for a lead but whose follow-up is too generic, too slow or too limited to email. It gives that lead a sales conversation across text, calls and WhatsApp.

What it does

Cenote describes HIPAA-compliant AI sales agents that reach out immediately, answer questions, qualify needs and keep following up as a shopper decides. The public use cases include abandoned carts, failed payments, win-backs and telehealth sales. Cenote homepage ↗ The company says teams can go live in seven days and opt out at any time; those are company claims, not an independently audited implementation guarantee.

The product is more interesting than a reminder blast because the agent carries context between channels and tries to complete the next action. A shopper can ask about a product, raise an objection, request a call later or move toward checkout without being handed back to a static campaign. For a high-consideration product, that persistent conversation is the actual wedge.

Evidence and constraints

Cenote’s published BetterMe Rx case study claims a threefold increase in abandoned-checkout recovery on the same segment, roughly 15% lift in company-wide conversions from that workflow and a move to the full checkout volume within a week. BetterMe Rx case study ↗ These are customer and company-reported results, not a general conversion benchmark. A buyer should ask for the denominator, consent flow, control comparison and the exact definition of “recovery” before using the numbers in a forecast.

The company’s founder context matches the product’s technical and healthcare ambition. The YC profile ↗ identifies Kofi Ansong as formerly at Google and Promise and Kristy Gao as formerly at Google, PayPal and Watershed. That background is useful context, but it does not replace a review of the proposed data handling, escalation path and clinical boundaries.

There is no public standard pricing table in the checked sources. The right commercial comparison is therefore against the margin in the abandoned funnel and the cost of human follow-up, not a guessed per-lead rate. In telehealth, confirm the exact scope of the HIPAA claim and which workflows remain human-owned before connecting patient data.

My editorial take

I would shortlist Cenote for a brand with meaningful abandoned demand, a narrow set of products and enough margin to support real conversations. I would start with one segment where the baseline is visible and require opt-out, human escalation and transcript review. For low-consideration products or a funnel with weak consent and messy product data, a conversational agent may simply scale the wrong experience.

Quick facts

Sources checked

Cenote’s YC profile, homepage and BetterMe Rx case-study page were checked on 2026-09-19.

Cohort context

Cenote is listed in Winter 2025. In our 2026-09-18 directory snapshot, 104 of 165 listed companies in that cohort have YC’s primary industry label B2B (63.0%). This is a current-directory comparison, not an original intake count or a performance ranking. Nine-cohort dataset.

Public website snapshot

Observed 2026-09-19 16:19 UTC in raw homepage HTML. This records visible metadata and advertised links, not agent execution or product quality.

Public observations · Collection method. Missing links here do not establish that a capability or file is absent elsewhere.